ZA951797B - Treatment of obsessive-compulsive disorders with 5-ht2 antagonists - Google Patents

Treatment of obsessive-compulsive disorders with 5-ht2 antagonists

Info

Publication number
ZA951797B
ZA951797B ZA951797A ZA951797A ZA951797B ZA 951797 B ZA951797 B ZA 951797B ZA 951797 A ZA951797 A ZA 951797A ZA 951797 A ZA951797 A ZA 951797A ZA 951797 B ZA951797 B ZA 951797B
Authority
ZA
South Africa
Prior art keywords
obsessive
antagonists
treatment
compulsive disorders
compulsive
Prior art date
Application number
ZA951797A
Other languages
English (en)
Inventor
Christopher Joseph Schmidt
Robert A Padich
John Herr Kehne
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of ZA951797B publication Critical patent/ZA951797B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
ZA951797A 1994-03-09 1995-03-03 Treatment of obsessive-compulsive disorders with 5-ht2 antagonists ZA951797B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/209,084 US5618824A (en) 1994-03-09 1994-03-09 Treatment of obsessive-compulsive disorders with 5-HT2 antagonists

Publications (1)

Publication Number Publication Date
ZA951797B true ZA951797B (en) 1996-12-03

Family

ID=22777257

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA951797A ZA951797B (en) 1994-03-09 1995-03-03 Treatment of obsessive-compulsive disorders with 5-ht2 antagonists

Country Status (15)

Country Link
US (1) US5618824A (ko)
EP (1) EP0749309A1 (ko)
JP (1) JP3861250B2 (ko)
KR (1) KR100360132B1 (ko)
CN (1) CN1143321A (ko)
AU (1) AU690968B2 (ko)
CA (1) CA2183954C (ko)
FI (1) FI963511A (ko)
HU (1) HU218948B (ko)
IL (1) IL112895A (ko)
NO (1) NO963731L (ko)
NZ (1) NZ281768A (ko)
TW (1) TW301606B (ko)
WO (1) WO1995024194A1 (ko)
ZA (1) ZA951797B (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2067937T3 (es) * 1990-06-01 1995-04-01 Merrell Dow Pharma (+)-alfa-(2,3-dimetoxifenil)-1-(2-(4-fluorofenil)etil)-4-piperidinametanol.
US6004980A (en) * 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
WO1997037935A1 (en) 1996-04-05 1997-10-16 Fmc Corporation METHOD FOR PREPARING SPINEL Li1+XMn2-XO4+Y INTERCALATION COMPOUNDS
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
US6228864B1 (en) * 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
US20050261341A1 (en) * 1998-03-13 2005-11-24 Aventis Pharmaceuticals Inc. Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US6713627B2 (en) * 1998-03-13 2004-03-30 Aventis Pharmaceuticals Inc. Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
TWI249526B (en) * 1998-03-13 2006-02-21 Aventis Pharma Inc Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
SE9801516D0 (sv) * 1998-04-30 1998-04-30 Maria Carlsson M100907/4-Piperidinemethanol derivatives for autism
US6277864B1 (en) 1998-08-28 2001-08-21 Aventis Pharmaceuticals Inc. Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders
ATE249830T1 (de) * 1998-08-28 2003-10-15 Aventis Pharma Inc Die verwendung von r (+)- g(a)-(2,3- dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4- piperidinemethanol zur behandlung von obstruktive schlafapnoe
US6939879B2 (en) * 1998-08-28 2005-09-06 Aventis Pharmaceuticals Inc. Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia
US6465490B1 (en) 1999-07-16 2002-10-15 Aventis Pharmaceuticals Inc. Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester
CA2374635C (en) * 1999-07-16 2007-04-17 Aventis Pharmaceuticals Inc. Sulfuric acid mono-[3-({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester
DE19934432A1 (de) 1999-07-22 2001-02-01 Merck Patent Gmbh Indolderivate
US20020099076A1 (en) * 2000-05-25 2002-07-25 Richard Scheyer D. Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
DE102004010132A1 (de) * 2004-02-27 2005-09-15 Merck Patent Gmbh Piperidinderivate
AU2005309960A1 (en) * 2004-11-22 2006-06-01 Mallinckrodt Inc. Process for the purification of benzphetamine hydrochloride
FR2956031B1 (fr) * 2010-02-11 2012-03-02 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc)
WO2017214442A1 (en) 2016-06-08 2017-12-14 President And Fellows Of Harvard College Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, rett syndrome, and fragile x syndrome
US11434244B2 (en) 2018-05-29 2022-09-06 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
EP3972595A4 (en) * 2019-05-22 2023-08-02 President and Fellows of Harvard College HUMAN TOUCH PRE-PULSE INHIBITION TEST
WO2021261471A1 (ja) * 2020-06-23 2021-12-30 国立大学法人京都大学 強迫性障害の治療剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783471A (en) * 1985-07-02 1988-11-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine methanol derivatives and the uses thereof
JPH02138214A (ja) * 1987-12-10 1990-05-28 Merrell Dow Pharmaceut Inc 不安を治療する方法
ZA891901B (en) * 1988-03-17 1989-11-29 Merrell Dow Pharma Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy
EP0436245A1 (en) * 1989-12-27 1991-07-10 Duphar International Research B.V Substituted 3,4-annelated benzimidazol-2(1H)-ones
US5288749A (en) * 1991-12-20 1994-02-22 Abbott Laboratories Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors
US5441961A (en) * 1992-08-27 1995-08-15 Eli Lilly And Company Substituted cyclo or bicycloalkylamides of (8β)-6-(substituted) ergolines
US5264576A (en) * 1992-10-22 1993-11-23 Hoechst-Roussel Pharmaceuticals Incorporated Pyrazolo[4,3-c]pyridines which are intermediates
WO1994014801A1 (en) * 1992-12-29 1994-07-07 Smithkline Beecham Plc Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
WO1995000131A1 (en) * 1993-06-23 1995-01-05 Cambridge Neuroscience, Incorporated Sigma receptor ligands and the use thereof
GB9313913D0 (en) * 1993-07-06 1993-08-18 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
TW301606B (ko) 1997-04-01
US5618824A (en) 1997-04-08
CN1143321A (zh) 1997-02-19
JPH09510441A (ja) 1997-10-21
AU690968B2 (en) 1998-05-07
KR970701544A (ko) 1997-04-12
CA2183954C (en) 2000-07-18
NO963731D0 (no) 1996-09-06
HU218948B (hu) 2001-01-29
NZ281768A (en) 2001-02-23
KR100360132B1 (ko) 2003-08-02
NO963731L (no) 1996-11-06
IL112895A0 (en) 1995-06-29
FI963511A0 (fi) 1996-09-06
AU1869495A (en) 1995-09-25
HUT75317A (en) 1997-05-28
JP3861250B2 (ja) 2006-12-20
HU9602449D0 (en) 1996-11-28
WO1995024194A1 (en) 1995-09-14
EP0749309A1 (en) 1996-12-27
IL112895A (en) 1999-12-31
CA2183954A1 (en) 1995-09-14
FI963511A (fi) 1996-09-06

Similar Documents

Publication Publication Date Title
ZA951797B (en) Treatment of obsessive-compulsive disorders with 5-ht2 antagonists
IL133800A0 (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
HUP0100069A3 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
EP1063990A4 (en) THERAPY FOR ESTROGEN RELATED DISORDERS
IL110204A0 (en) Novel indolene derivatives, processes for their preparation and their use for the treatment of cns disorders
EP0820467A4 (en) METHODS OF TREATING EYE DISORDERS
IL115664A0 (en) Treatment of disorders with duloxetine
EP0698742A3 (en) Swivel carabiner
EP1126850A4 (en) TREATMENT OF CONDITIONS OF THE RETINA
PH31326A (en) Methods of inhibiting breast disorders.
PL345769A1 (en) Triazolopyridines for the treatment of thrombosis disorders
HK1112738A1 (en) Arylsulfonamides and analogues as well as use for the treatment of neuro- degenerative disorders
PL332313A1 (en) Application of benzopyranoles in treatment of neurological disorders
HK1038510B (zh) 使用神經營養因子興奮劑治療眼神經變性疾病
HRP970224A2 (en) TREATMENT OF ASTHMA WITH TNFR-Ig
GB9518887D0 (en) Treatment of muscular disorders
ZA947912B (en) Treatment of medical disorders associated with free radical formation
ZA9410076B (en) Methods of inhibiting obsessive-compulsive and consumptive disorders
GB9420080D0 (en) The treatment of liquids
GB9408651D0 (en) Bath fitting
PT1011678E (pt) Utilização de mecamilamina para o tratamento de perturbações neuropsiquiátricas responsivas à nicotina.
ZA985818B (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders.
ZA937604B (en) 3,3-disubstituted tri and tetracyclic indolin-2-ones useful for the treatment of cognitive disorders
GB9413556D0 (en) The treatment of neurological and psychiatric disorders
GB2292682B (en) Adjustable bath seat